G. Ross

2.6k total citations · 1 hit paper
48 papers, 1.8k citations indexed

About

G. Ross is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Ross has authored 48 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 16 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Ross's work include Lung Cancer Research Studies (16 papers), Cancer therapeutics and mechanisms (15 papers) and HER2/EGFR in Cancer Research (14 papers). G. Ross is often cited by papers focused on Lung Cancer Research Studies (16 papers), Cancer therapeutics and mechanisms (15 papers) and HER2/EGFR in Cancer Research (14 papers). G. Ross collaborates with scholars based in United Kingdom, United States and Germany. G. Ross's co-authors include Javier Cortés, Andreas Schneeweiß, Virginia McNally, Christoph Tausch, Roberto Hegg, V. Harvey, Tamas Hickish, Alexandru Eniu, Jayantha Ratnayake and Stephen Chia and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

G. Ross

48 papers receiving 1.8k citations

Hit Papers

Pertuzumab plus trastuzumab in combination with standard ... 2013 2026 2017 2021 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
    2013 774 citations Andreas Schneeweiß, Stephen Chia et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Ross United Kingdom 18 1.4k 567 539 309 298 48 1.8k
R. Largillier France 14 940 0.7× 527 0.9× 198 0.4× 162 0.5× 334 1.1× 47 1.5k
Holm Eggemann Germany 22 694 0.5× 651 1.1× 145 0.3× 231 0.7× 238 0.8× 76 1.6k
Theresa L. Werner United States 24 779 0.6× 271 0.5× 117 0.2× 501 1.6× 247 0.8× 99 1.7k
Maurizio Cosimelli Italy 27 1.6k 1.2× 228 0.4× 289 0.5× 422 1.4× 562 1.9× 103 2.5k
H. Curé France 22 1.2k 0.9× 742 1.3× 118 0.2× 183 0.6× 327 1.1× 82 2.0k
Federico Piacentini Italy 23 1.3k 1.0× 718 1.3× 328 0.6× 386 1.2× 517 1.7× 115 1.9k
Daniel Vorobiof South Africa 18 938 0.7× 300 0.5× 94 0.2× 153 0.5× 390 1.3× 61 1.6k
Filipa Lynce United States 21 1.3k 0.9× 474 0.8× 146 0.3× 571 1.8× 456 1.5× 110 1.9k
Kathryn P. Gray United States 22 959 0.7× 657 1.2× 152 0.3× 622 2.0× 1.0k 3.5× 75 2.0k
Malgorzata Tuxen Denmark 18 687 0.5× 318 0.6× 153 0.3× 394 1.3× 282 0.9× 33 1.8k

Countries citing papers authored by G. Ross

Since Specialization
Citations

This map shows the geographic impact of G. Ross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Ross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Ross more than expected).

Fields of papers citing papers by G. Ross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Ross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Ross. The network helps show where G. Ross may publish in the future.

Co-authorship network of co-authors of G. Ross

This figure shows the co-authorship network connecting the top 25 collaborators of G. Ross. A scholar is included among the top collaborators of G. Ross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Ross. G. Ross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dillon, Magnus T., Aude Espinasse, Sally Ellis, et al.. (2017). A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A). UCL Discovery (University College London). 1 indexed citations
2.
Schneeweiß, Andreas, Stephen Chia, Tamas Hickish, et al.. (2013). Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology. 24(9). 2278–2284. 774 indexed citations breakdown →
3.
Cortés, Javier, José Baselga, Young‐Hyuck Im, et al.. (2013). Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Annals of Oncology. 24(10). 2630–2635. 52 indexed citations
4.
5.
Lenihan, Daniel J., et al.. (2011). Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology. 23(3). 791–800. 93 indexed citations
6.
Baselga, José, et al.. (2011). OT1-02-04: Adjuvant Pertuzumab and Herceptin IN IniTial TherapY of Breast Cancer: APHINITY (BIG 4–11/BO25126/TOC4939g).. Cancer Research. 71(24_Supplement). OT1–2. 10 indexed citations
7.
Gianni, Luca, Tadeusz Pieńkowski, Y-H Im, et al.. (2010). Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere'). Cancer Research. 70(24_Supplement). S3–2. 48 indexed citations
8.
9.
Rezvani, M. & G. Ross. (2004). Modification of radiation‐induced acute oral mucositis in the rat. International Journal of Radiation Biology. 80(2). 177–182. 38 indexed citations
10.
Huinink, W. ten Bokkel, Stephen Lane, & G. Ross. (2003). Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of Oncology. 15(1). 100–103. 86 indexed citations
11.
Pawel, Joachim von, et al.. (2003). 789 A meta-analysis of efficacy data from two randomised studies on oral topotecan in patients with relapsed SCLC. European Journal of Cancer Supplements. 1(5). S237–S237. 1 indexed citations
12.
Gore, Martin, Amit M. Oza, Gordon Rustin, et al.. (2002). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European Journal of Cancer. 38(1). 57–63. 82 indexed citations
13.
Calvert, Paula, Alan V. Boddy, Martin J. Griffin, et al.. (2002). Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Annals of Oncology. 13(3). 399–402. 9 indexed citations
14.
Pujol, Jean-Louis, Joachim von Pawel, Salvatore Tumolo, et al.. (2001). Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer. Oncology. 61(Suppl. 1). 47–54. 10 indexed citations
15.
Cesano, Alessandra, Stephen Lane, G. Ross, & Scott Z. Fields. (2000). Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients.. International Journal of Oncology. 17(3). 587–90. 10 indexed citations
16.
Rezvani, M., Elizabeth Whitehouse, J. Wilkinson, et al.. (2000). Effects of Lipochromin and Levosinum in the modulation of radiation-induced injury to pig skin.. British Journal of Radiology. 73(871). 771–775. 4 indexed citations
17.
Morris, Garrett M., et al.. (1997). Modulation of the cell kinetics of pig skin by the topical application of evening primrose oil or Lioxasol. Cell Proliferation. 30(8-9). 311–323. 9 indexed citations
18.
Pawel, Joachim von, K. Hans, D Moro, et al.. (1997). Topotecan (Hycamtin™) in small cell lung cancer (SCLC) after failure of first line therapy: Multicentre phase II study. European Journal of Cancer. 33. S229–S229. 15 indexed citations
19.
Morris, Garrett M., et al.. (1993). Boron Neutron Capture Therapy: Long-Term Effects on the Skin and Spinal Cord of the Rat. Radiation Research. 135(3). 380–380. 10 indexed citations
20.
Ross, G., et al.. (1993). The modulation of radiation-induced damage to pig skin by essential fatty acids. British Journal of Cancer. 68(1). 1–7. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Largillier Breakdown of academic impact, for papers by Holm Eggemann Breakdown of academic impact, for papers by Theresa L. Werner Breakdown of academic impact, for papers by Maurizio Cosimelli Breakdown of academic impact, for papers by H. Curé Breakdown of academic impact, for papers by Federico Piacentini Breakdown of academic impact, for papers by Daniel Vorobiof Breakdown of academic impact, for papers by Filipa Lynce Breakdown of academic impact, for papers by Kathryn P. Gray Breakdown of academic impact, for papers by Malgorzata Tuxen
Rankless by CCL
2026